Targeted approaches to induce immune tolerance for Pompe disease therapy

Phillip A. Doerfler, Sushrusha Nayak, Manuela Corti, Laurence Morel, Roland W. Herzog, Barry J. Byrne

Research output: Contribution to journalReview articlepeer-review

42 Scopus citations


Enzyme and gene replacement strategies have developed into viable therapeutic approaches for the treatment of Pompe disease (acid α-glucosidase (GAA) deficiency). Unfortunately, the introduction of GAA and viral vectors encoding the enzyme can lead to detrimental immune responses that attenuate treatment benefits and can impact patient safety. Preclinical and clinical experience in addressing humoral responses toward enzyme and gene therapy for Pompe disease have provided greater understanding of the immunological consequences of the provided therapy. B- and T-cell modulation has been shown to be effective in preventing infusion-associated reactions during enzyme replacement therapy in patients and has shown similar success in the context of gene therapy. Additional techniques to induce humoral tolerance for Pompe disease have been the targeted expression or delivery of GAA to discrete cell types or tissues such as the gut-associated lymphoid tissues, red blood cells, hematopoietic stem cells, and the liver. Research into overcoming preexisting immunity through immunomodulation and gene transfer are becoming increasingly important to achieve long-term efficacy. This review highlights the advances in therapies as well as the improved understanding of the molecular mechanisms involved in the humoral immune response with emphasis on methods employed to overcome responses associated with enzyme and gene therapies for Pompe disease.

Original languageEnglish (US)
Pages (from-to)15053
Number of pages1
JournalMolecular Therapy Methods and Clinical Development
StatePublished - Mar 16 2016
Externally publishedYes

ASJC Scopus subject areas

  • Genetics
  • Molecular Medicine
  • Molecular Biology


Dive into the research topics of 'Targeted approaches to induce immune tolerance for Pompe disease therapy'. Together they form a unique fingerprint.

Cite this